Ready for risk? Alnylam may be right for you; Catabasis takes its cholesterol drug into PhII;

@FierceBiotech: Dana-Farber researchers highlight progress with new drugs for acute myeloid leukemia. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: Eyeing pivotal PhIIIs, Margolin nabs $53M crossover round for Allena. News | Follow @JohnCFierce

@DamianFierce: "You know, at the right price these guys basically will do anything." More from Bloomberg | Follow @DamianFierce

> Alnylam's ($ALNY) Chief Human Resources Officer Karen Anderson tells The Boston Globe that the biotech is planning on recruiting close to 1,500 new staffers in the next 5 years, including a batch of workers from the hundreds being laid off at Biogen's ($BIIB) Boston facilities. "I don't want the same people that Pfizer ($PFE) wants," she says. "I need people who are ready for a risk." Story

> Catabasis Pharmaceuticals ($CATB) kicked off a Phase IIa trial of its treatment for high cholesterol, enrolling about 150 patients to test how well its oral therapy can reduce LDL cholesterol. More

> The growing scourge of non-alcoholic steatohepatitis, or NASH, has spurred a bevy of drugmakers into a race to develop the first approved treatment for the liver disease. Feature

Medical Device News

@FierceMedDev: Scientists roll out 3-D printed self-assembling blood vessels. Article | Follow @FierceMedDev

@EmilyWFierce: Pharma ad budgets stay flat, even as spending jumps across the board: Report. FiercePharmaMarketing story | Follow @EmilyWFierce

> Illumina Accelerator discloses its latest funded class of four genomic startups. Story

> Top gynecologists push back at FDA crackdown on power morcellator devices. Report

> Chemotherapy cooling cap to reduce hair loss for breast cancer patients gets FDA nod. Article

Pharma News

@FiercePharma: Allergy Therapeutics brings long-delayed grass allergy vax into PhII. FierceVaccines story | Follow @FiercePharma

@CarlyHFierce: ICYMI: AbbVie's Imbruvica, Amgen's Kyprolis shine at annual ASH meeting. More | Follow @CarlyHFierce

> Lilly's split of animal and human drug production does not bode a spinoff, execs insist. Report

> Advera: Harvoni bests Sovaldi, Viekira Pak in hep C drug safety. Article

Biotech Research News

> New screening tech at Scripps spotlights diabetes drug candidates. Item

> Dana-Farber researchers highlight progress with new drugs for acute myeloid leukemia. More

> Imperial College scientists engineer a CRISPR/Cas9 breakthrough on malaria. Report

> Florida U team's gene therapy safeguards cognition in rats. Story

> Epilepsy scientific meeting highlights promise of cannabidiol for reducing seizures. Article

Pharma Marketing News

> Can new PhIII data help Gilead's Zydelig stage a comeback in CLL? Article

> Pharma ad budgets stay flat, even as spending jumps across the board: Report. More

> Gilead's Harvoni beats Sovaldi, AbbVie's Viekira Pak in hep C drug safety: Advera. Story

> Cancer-free President Carter notes Keytruda treatment: Will the celebrity effect kick in? More

> With Paris spotlight on climate change, here's how Big Pharma stacks up. Article

Vaccines News

> Second flu shot helps cancer patients stave off infection, Yale team says. Item

> Japan's Kaketsuken covered up illicit blood product, vaccine production methods for 40 years. More

> Cerberus Capital management invests $105M in PaxVax. Report

> Allergy Therapeutics brings long-delayed grass allergy vax into PhII. Story

> U.S. Army, Hawaii Biotech join for dengue vaccine effort. Article

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.